Fallopian tube carcinoma

Summary

Fallopian tube carcinoma (MONDO:0006206) is a cancer (an umbrella term covering 6 Mondo subtypes) with 2 cohort genes (2 CIViC-evidence somatic drivers) and 697 clinical trials. Molecularly, BRCA1 Mutation OR BRCA2 Mutation confers sensitivity to Niraparib in Fallopian Tube Carcinoma (CIViC Level A). Top therapeutic interventions include paclitaxel, topotecan, and mirvetuximab soravtansine.

At a glance

• Classification: Cancer
• Umbrella term: 6 Mondo subtypes
• Cohort genes: 2
• Clinical trials: 697
• Precision-medicine evidence (CIViC): 1 subtype–drug association

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	fallopian tube carcinoma
Mondo ID	MONDO:0006206
EFO	EFO:1000251
DOID	DOID:1963
NCIT	C3867
SNOMED CT	276870001
UMLS	C0238122
MedGen	66762
GARD	0024329
Anatomy (UBERON)	UBERON:0003889
Is cancer (heuristic)	yes

Also known as: cancer of fallopian tube · cancer of the fallopian tube · carcinoma of fallopian tube · carcinoma of the fallopian tube · fallopian tube cancer · fallopian tube carcinoma

Data availability: 2 cell lines.

Disease family

An umbrella term covering 6 Mondo subtypes.

Classification path: disease › human disease › disease by etiologic mechanism › cancer or benign tumor › neoplastic disease or syndrome › neoplasm › cancer › reproductive system cancer › female reproductive organ cancer › fallopian tube cancer › fallopian tube carcinoma

Related subtypes (3): fallopian tube leiomyosarcoma, fallopian tube adenosarcoma, cancer of isthmus of fallopian tube

Subtypes (6): fallopian tube adenocarcinoma, fallopian tube transitional cell carcinoma, fallopian tube squamous cell carcinoma, hereditary fallopian tube carcinoma, fallopian tube gestational choriocarcinoma, fallopian tube carcinosarcoma

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

Mendelian disease overlap and somatic drivers

GenCC: 0 · Orphanet: 21 · OMIM-shared: 0 · Dual-evidence (GWAS+Mendelian): 0

Somatic driver evidence (intOGen + CIViC, cohort fanout)

Gene	intOGen role	Cancer types	CIViC
BRCA1	LoF	BLCA,BRCA,MEL,OVT	CIViC #6
BRCA2	LoF	BLCA,BRCA,CESC,CHOL,HCC,HNSC,LUSC,MBL,OVT,PAAD,PRAD,PROSTATE,RCC,VULVA	CIViC #7

Orphanet rare-disease linkage (cohort genes)

Gene	Orphanet ID	Rare disease
BRCA1	Orphanet:1331	Familial prostate cancer
BRCA1	Orphanet:1333	Familial pancreatic carcinoma
BRCA1	Orphanet:145	Hereditary breast and/or ovarian cancer syndrome
BRCA1	Orphanet:168829	Primary peritoneal carcinoma
BRCA1	Orphanet:227535	Hereditary breast cancer
BRCA1	Orphanet:667662	Breast implant-associated anaplastic large cell lymphoma
BRCA1	Orphanet:694963	Inflammatory breast cancer
BRCA1	Orphanet:70567	Cholangiocarcinoma
BRCA1	Orphanet:84	Fanconi anemia
BRCA2	Orphanet:1331	Familial prostate cancer
BRCA2	Orphanet:1333	Familial pancreatic carcinoma
BRCA2	Orphanet:145	Hereditary breast and/or ovarian cancer syndrome
BRCA2	Orphanet:178	Chordoma
BRCA2	Orphanet:227535	Hereditary breast cancer
BRCA2	Orphanet:319462	Inherited cancer-predisposing syndrome due to biallelic BRCA2 mutations
BRCA2	Orphanet:440437	Familial colorectal cancer Type X
BRCA2	Orphanet:654	Nephroblastoma
BRCA2	Orphanet:667662	Breast implant-associated anaplastic large cell lymphoma
BRCA2	Orphanet:694963	Inflammatory breast cancer
BRCA2	Orphanet:70567	Cholangiocarcinoma
BRCA2	Orphanet:84	Fanconi anemia

Cohort genes → proteins

2 cohort genes, 2 distinct canonical proteins.

Evidence partition

Subset	Genes
civic_only	2

Cohort genes (full)

Symbol	HGNC	Ensembl	UniProt	Name	Evidence
BRCA1	HGNC:1100	ENSG00000012048	P38398	Breast cancer type 1 susceptibility protein	civic_evidence
BRCA2	HGNC:1101	ENSG00000139618	P51587	Breast cancer type 2 susceptibility protein	civic_evidence

Cohort function summary

Lead sentence per gene, UniProt-curated.

Symbol	Protein name	Function (lead sentence)
BRCA1	Breast cancer type 1 susceptibility protein	E3 ubiquitin-protein ligase that specifically mediates the formation of ‘Lys-6’-linked polyubiquitin chains and plays a central role in DNA repair by facilitating cellular responses to DNA damage.
BRCA2	Breast cancer type 2 susceptibility protein	Involved in double-strand break repair and/or homologous recombination.

Protein-family classification

Druggable: 0 · Difficult: 1 · Unknown: 1 · Druggable fraction: 0.0

Family distribution

Cohort families vs a genome-wide background (hypergeometric, BH-FDR; fold = observed/expected). Counts kept; sorted by enrichment, so the catch-all Other/Unknown bucket no longer leads.

Family	Genes	Fold	FDR
Transcription factor	1	4.1×	0.455
Other/Unknown	1	0.9×	0.805

Per-gene assignment

Symbol	Family	Druggable?	EC	InterPro (top 3)
BRCA1	Transcription factor	no	2.3.2.27	BRCT_dom, Znf_RING, BRCA1
BRCA2	Other/Unknown	no		BRCA2_repeat, NA-bd_OB-fold, BRCA2_OB_1

Expression context

Cohort genes with no expression data: 0.

2 cohort genes are a single-cell marker in ≥1 SCXA experiment.

Breadth distribution (Bgee present_calls)

Bucket	Genes
narrow (1-5 tissues)	0
moderate (6-20)	0
broad (>20)	2
unknown	0

Top tissues across cohort

Tissue	Cohort genes
male germ line stem cell (sensu Vertebrata) in testis	2
ventricular zone	2
primordial germ cell in gonad	1
secondary oocyte	1

Per-gene tissue summary (top 30)

Symbol	Bgee breadth	FANTOM5 breadth	SCXA	Top tissues
BRCA1	208	ubiquitous	marker	ventricular zone, male germ line stem cell (sensu Vertebrata) in testis, primordial germ cell in gonad
BRCA2	184	ubiquitous	marker	male germ line stem cell (sensu Vertebrata) in testis, secondary oocyte, ventricular zone

Protein interactions among cohort

Intra-cohort edges: 1.

Hub genes (top 10 by interactor count)

Symbol	Interactor count
BRCA1	9,064
BRCA2	4,839

Intra-cohort edges

A	B	Sources
BRCA1	BRCA2	string_interaction

Structural data

PDB: 2 · AlphaFold-only: 0 · No structure: 0

Cohort genes with PDB structures (top 30)

Symbol	UniProt	PDB entries
BRCA1	P38398	33
BRCA2	P51587	14

Function

Pathway analysis

Distinct Reactome pathways touched by cohort: 62. Enrichment computed across 2 evidence-associated genes (2 with Reactome annotation).

Pathways by enrichment

Over-representation of cohort genes vs the genome-wide background (hypergeometric test, Benjamini-Hochberg FDR; fold = observed/expected over 2 annotated cohort genes). Counts and members are kept as ground-truth; sorted by enrichment.

Pathway	Cohort genes	Fold	FDR	Sample cohort genes
Defective homologous recombination repair (HRR) due to PALB2 loss of function	2	951.7×	3e-05	BRCA1, BRCA2
Diseases of DNA Double-Strand Break Repair	2	815.7×	3e-05	BRCA1, BRCA2
Defective homologous recombination repair (HRR) due to BRCA2 loss of function	2	815.7×	3e-05	BRCA1, BRCA2
Resolution of D-Loop Structures	2	634.4×	4e-05	BRCA1, BRCA2
Diseases of DNA repair	2	571.0×	4e-05	BRCA1, BRCA2
Impaired BRCA2 binding to PALB2	2	456.8×	4e-05	BRCA1, BRCA2
Defective homologous recombination repair (HRR) due to BRCA1 loss of function	2	423.0×	4e-05	BRCA1, BRCA2
Defective HDR through Homologous Recombination Repair (HRR) due to PALB2 loss of BRCA1 binding function	2	423.0×	4e-05	BRCA1, BRCA2
Defective HDR through Homologous Recombination Repair (HRR) due to PALB2 loss of BRCA2/RAD51/RAD51C binding function	2	423.0×	4e-05	BRCA1, BRCA2
Resolution of D-loop Structures through Synthesis-Dependent Strand Annealing (SDSA)	2	393.8×	4e-05	BRCA1, BRCA2
Homologous DNA Pairing and Strand Exchange	2	380.7×	4e-05	BRCA1, BRCA2
Homology Directed Repair	2	308.6×	4e-05	BRCA1, BRCA2
HDR through Homologous Recombination (HRR) or Single Strand Annealing (SSA)	2	308.6×	4e-05	BRCA1, BRCA2
Impaired BRCA2 binding to RAD51	2	308.6×	4e-05	BRCA1, BRCA2
Resolution of D-loop Structures through Holliday Junction Intermediates	2	300.5×	4e-05	BRCA1, BRCA2
Meiosis	2	285.5×	5e-05	BRCA1, BRCA2
Presynaptic phase of homologous DNA pairing and strand exchange	2	271.9×	5e-05	BRCA1, BRCA2
DNA Double-Strand Break Repair	2	248.3×	5e-05	BRCA1, BRCA2
Reproduction	2	190.3×	8e-05	BRCA1, BRCA2
HDR through Homologous Recombination (HRR)	2	190.3×	8e-05	BRCA1, BRCA2
Meiotic recombination	2	129.8×	2e-04	BRCA1, BRCA2
DNA Repair	2	98.5×	3e-04	BRCA1, BRCA2
Defective DNA double strand break response due to BRCA1 loss of function	1	2855.0×	9e-04	BRCA1
Defective DNA double strand break response due to BARD1 loss of function	1	2855.0×	9e-04	BRCA1
Impaired BRCA2 translocation to the nucleus	1	1903.3×	0.001	BRCA2
Impaired BRCA2 binding to SEM1 (DSS1)	1	1903.3×	0.001	BRCA2
Cell Cycle	2	36.0×	0.002	BRCA1, BRCA2
Regulation of MITF-M-dependent genes involved in DNA replication, damage repair and senescence	1	815.7×	0.003	BRCA1
HDR through MMEJ (alt-NHEJ)	1	439.2×	0.005	BRCA2
DNA Double Strand Break Response	1	237.9×	0.009	BRCA1

GO biological processes by enrichment

Over-representation of cohort genes vs the genome-wide background (hypergeometric test, Benjamini-Hochberg FDR; fold = observed/expected over 2 annotated cohort genes). Counts and members are kept as ground-truth; sorted by enrichment.

GO term	Cohort genes	Fold	FDR	Sample cohort genes
regulation of DNA damage checkpoint	2	1123.5×	5e-05	BRCA1, BRCA2
cellular response to ionizing radiation	2	411.0×	2e-04	BRCA1, BRCA2
double-strand break repair	2	203.0×	5e-04	BRCA1, BRCA2
double-strand break repair via homologous recombination	2	156.0×	7e-04	BRCA1, BRCA2
mitotic recombination-dependent replication fork processing	1	4213.0×	0.003	BRCA2
negative regulation of mammary gland epithelial cell proliferation	1	1685.2×	0.005	BRCA2
cellular response to indole-3-methanol	1	1685.2×	0.005	BRCA1
chordate embryonic development	1	1404.3×	0.006	BRCA1
negative regulation of centriole replication	1	1203.7×	0.006	BRCA1
establishment of protein localization to telomere	1	1053.2×	0.006	BRCA2
DNA strand resection involved in replication fork processing	1	1053.2×	0.006	BRCA1
DNA damage tolerance	1	842.6×	0.006	BRCA1
response to UV-C	1	842.6×	0.006	BRCA2
telomere maintenance via recombination	1	766.0×	0.006	BRCA2
positive regulation of DNA-templated transcription	2	27.9×	0.006	BRCA1, BRCA2
homologous recombination	1	702.2×	0.006	BRCA1
negative regulation of intracellular estrogen receptor signaling pathway	1	561.7×	0.006	BRCA1
negative regulation of gene expression via chromosomal CpG island methylation	1	526.6×	0.006	BRCA1
inner cell mass cell proliferation	1	495.6×	0.006	BRCA2
protein K6-linked ubiquitination	1	495.6×	0.006	BRCA1
centrosome duplication	1	468.1×	0.006	BRCA2
random inactivation of X chromosome	1	468.1×	0.006	BRCA1
negative regulation of reactive oxygen species metabolic process	1	468.1×	0.006	BRCA1
response to X-ray	1	443.5×	0.006	BRCA2
negative regulation of fatty acid biosynthetic process	1	443.5×	0.006	BRCA1
female gonad development	1	401.2×	0.006	BRCA2
mitotic G2/M transition checkpoint	1	401.2×	0.006	BRCA1
hematopoietic stem cell proliferation	1	324.1×	0.007	BRCA2
oocyte maturation	1	300.9×	0.007	BRCA2
male meiosis I	1	290.6×	0.007	BRCA2

Therapeutics

Drugs indicated for this disease

1 approved, 8 in late-stage (phase 3) trials. Disease-direct ChEMBL indications, not inferred from the associated-gene cohort below.

Drug	Development status
Bevacizumab	Approved (phase 4)
Atezolizumab	Phase 3 (in late-stage trials)
Carboplatin	Phase 3 (in late-stage trials)
Cisplatin	Phase 3 (in late-stage trials)
Doxorubicin	Phase 3 (in late-stage trials)
Gemcitabine	Phase 3 (in late-stage trials)
Ifosfamide	Phase 3 (in late-stage trials)
Paclitaxel	Phase 3 (in late-stage trials)
Tamoxifen	Phase 3 (in late-stage trials)

Earlier-phase candidates (phase 2, investigational — efficacy not yet established): Aldesleukin, Capecitabine, Catumaxomab, Cetuximab, Decitabine, Denileukin Diftitox, Durvalumab, Enzastaurin, Gefitinib, Letrozole, Olaparib, Oxaliplatin, Pembrolizumab, Pemetrexed, Relacorilant, Ribociclib, Sargramostim, Sunitinib, Temsirolimus, Topotecan, Tremelimumab.

Drug target analysis

Approved (phase 4): 1 · Phase ≥3: 1 · Phased (≥1): 1 · Undrugged: 1

Druggability breadth: 1 of 2 evidence-associated genes (50%) have a ChEMBL target (buckets above are over the deeply-mined display cohort).

Genes with an approved drug

The molecule shown is one approved compound that hits the gene — not necessarily a drug of choice or one indicated for this disease.

Symbol	Example approved molecule
BRCA1	RIBOFLAVIN

Top cohort targets by molecule count

Symbol	Molecules	Max phase
BRCA1	12	4
BRCA2	0	0

Drugs targeting cohort genes (top 30)

Molecule	Max phase	Targets in cohort
RIBOFLAVIN	4	BRCA1
DAUNORUBICIN HYDROCHLORIDE	4	BRCA1
TOPOTECAN HYDROCHLORIDE	4	BRCA1
DAUNORUBICIN	4	BRCA1
DOXORUBICIN HYDROCHLORIDE	4	BRCA1
MESALAMINE	4	BRCA1
DIPYRIDAMOLE	4	BRCA1
CURCUMIN	3	BRCA1
SURAMIN	3	BRCA1
SURAMIN HEXASODIUM	3	BRCA1
SODIUM TANSHINONE IIA SULFONATE	2	BRCA1
HOMIDIUM BROMIDE	2	BRCA1

Bioactivity and enzyme data

Enzyme cohort genes (≥1 EC): 1.

Cohort genes with ChEMBL bioactivity (full, sorted by assay count)

Symbol	Assays	Type breakdown
BRCA1	13	Binding:9, Functional:4

Cohort enzymes (BRENDA EC)

Symbol	EC numbers	Names
BRCA1	2.3.2.27	RING-type E3 ubiquitin transferase

Pharmacogenomics

Cohort genes with a PharmGKB record: 2; with CPIC/DPWG dosing guidelines: 0.

No cohort gene has a CPIC/DPWG genotype-guided dosing guideline (PharmGKB).

Drug repurposing candidates

12 approved/phased drugs hit cohort targets but don’t yet appear in disease-level clinical trials. Target-inhibition rationale is strongest for cancer driver genes; a bioactivity hit is a screening signal, not a treatment claim.

Compound	Max phase	Cohort target (bioactivity)
RIBOFLAVIN	4	BRCA1
DAUNORUBICIN HYDROCHLORIDE	4	BRCA1
TOPOTECAN HYDROCHLORIDE	4	BRCA1
DAUNORUBICIN	4	BRCA1
DOXORUBICIN HYDROCHLORIDE	4	BRCA1
MESALAMINE	4	BRCA1
DIPYRIDAMOLE	4	BRCA1
CURCUMIN	3	BRCA1
SURAMIN	3	BRCA1
SURAMIN HEXASODIUM	3	BRCA1
SODIUM TANSHINONE IIA SULFONATE	2	BRCA1
HOMIDIUM BROMIDE	2	BRCA1

Druggability pyramid

Cohort genes binned by druggability tier (high → low):

Tier	Definition	Genes	Symbols
A	Approved (phase 4 drug)	1	BRCA1
B	Phased (≥1) drug, not yet approved	0
C	Druggable family + PDB, no drug	0
D	Druggable family + AlphaFold only, no drug	0
E	Difficult family or no structure, no drug	1	BRCA2

Undrugged target profiles

1 cohort genes are undrugged. Ranked by ‘starting-point quality’ (assay depth + drugged-partner adjacency).

Symbol	ChEMBL assays	Drugged partners (top 3)
BRCA2	0	BRCA1

Clinical trials & evidence

Clinical trials

Clinical trials: 697.

Phase distribution (across all retrieved trials)

Phase	Trials
PHASE2	264
PHASE1	156
Not specified	107
PHASE3	75
PHASE1/PHASE2	68
EARLY_PHASE1	18
PHASE2/PHASE3	8
PHASE4	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT06972693	PHASE4	ACTIVE_NOT_RECRUITING	NGS-based Germline and Somatic Genetic Test in Ovarian Carcinoma
NCT00565851	PHASE3	ACTIVE_NOT_RECRUITING	Carboplatin, Paclitaxel and Gemcitabine Hydrochloride With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian, Epithelial, Primary Peritoneal, or Fallopian Tube Cancer
NCT01081262	PHASE3	ACTIVE_NOT_RECRUITING	Carboplatin and Paclitaxel or Oxaliplatin and Capecitabine With or Without Bevacizumab as First-Line Therapy in Treating Patients With Newly Diagnosed Stage II-IV or Recurrent Stage I Epithelial Ovarian or Fallopian Tube Cancer
NCT01167712	PHASE3	ACTIVE_NOT_RECRUITING	Paclitaxel and Carboplatin With or Without Bevacizumab in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer
NCT02446600	PHASE3	ACTIVE_NOT_RECRUITING	Testing the Use of A Single Drug (Olaparib) or the Combination of Two Drugs (Cediranib and Olaparib) Compared to the Usual Chemotherapy for Women With Platinum Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
NCT02502266	PHASE2/PHASE3	ACTIVE_NOT_RECRUITING	Testing the Combination of Cediranib and Olaparib in Comparison to Each Drug Alone or Other Chemotherapy in Recurrent Platinum-Resistant Ovarian Cancer
NCT02839707	PHASE2/PHASE3	ACTIVE_NOT_RECRUITING	Pegylated Liposomal Doxorubicin Hydrochloride With Atezolizumab and/or Bevacizumab in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
NCT02859038	PHASE3	ACTIVE_NOT_RECRUITING	Study of Upfront Surgery Versus Neoadjuvant Chemotherapy in Patients With Advanced Ovarian Cancer (SUNNY)
NCT03522246	PHASE3	ACTIVE_NOT_RECRUITING	A Study in Ovarian Cancer Patients Evaluating Rucaparib and Nivolumab as Maintenance Treatment Following Response to Front-Line Platinum-Based Chemotherapy
NCT04095364	PHASE3	ACTIVE_NOT_RECRUITING	Letrozole With or Without Paclitaxel and Carboplatin in Treating Patients With Stage II-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
NCT04515602	PHASE3	NOT_YET_RECRUITING	Stratified Evaluation of PDS and NACT-IDS in Ovarian Cancer (FOCUS)
NCT04575935	PHASE3	RECRUITING	Minimally Invasive Surgery After Neoadjuvant Chemotherapy for the Treatment of Stage IIIC-IV Ovarian, Primary Peritoneal, or Fallopian Tube Cancer, LANCE Trial
NCT05009082	PHASE3	RECRUITING	Niraparib vs Niraparib Plus Bevacizumab in Patients With Platinum/Taxane-based Chemotherapy in Advanced Ovarian Cancer
NCT05281471	PHASE3	RECRUITING	Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician’s Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076)
NCT05445778	PHASE3	ACTIVE_NOT_RECRUITING	Mirvetuximab Soravtansine With Bevacizumab Versus Bevacizumab as Maintenance in Platinum-sensitive Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer
NCT05659381	PHASE3	RECRUITING	Heated Intraperitoneal Chemotherapy Followed by Niraparib for Ovarian, Primary Peritoneal and Fallopian Tube Cancer
NCT05737303	PHASE3	RECRUITING	Nab-paclitaxel Versus Sb-taxanes As First-Line Treatment in Advanced Ovarian Cancer
NCT06751485	PHASE3	NOT_YET_RECRUITING	JSKN003 in Platinum-Resistant, Relapsed Epithelial Ovarian Cancer
NCT06824467	PHASE3	RECRUITING	A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103)
NCT06834672	PHASE3	RECRUITING	Study of IBI354 Versus Investigator’s Choice of Chemotherapy in Patients With Platinum-resistant Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
NCT06915025	PHASE3	RECRUITING	Phase 3 Trial Evaluating the Safety & Efficacy of IMNN-001 Administered in Combination w/ Standard NACT & Adjuvant Chemotherapy in Newly Diagnosed Patients w/ Advanced EOC, Fallopian Tube or Primary Peritoneal Cancer
NCT06994195	PHASE3	RECRUITING	A Study Comparing BL-B01D1 With the Investigator’s Choice of Chemotherapy in Patients With Platinum-resistant Recurrent Epithelial Ovarian Cancer(PANKU-GYN01)
NCT07472140	PHASE2/PHASE3	RECRUITING	PARP (Poly (ADP-ribose) Polymerase) Inhibitor With or Without Angiogenesis Inhibitor in Homologous Recombination Deficient Primary Ovarian Cancer, Fallopian-Tube Cancer, or Primary Peritoneal Cancer
NCT07545460	PHASE3	NOT_YET_RECRUITING	A Study Comparing BL-M07D1 With Physician’s Choice of Chemotherapy in Patients With HER2-Expressing Platinum-Resistant Recurrent Epithelial Ovarian Cancer, Fallopian Tube Cancer, and Primary Peritoneal Cancer
NCT00002895	PHASE3	COMPLETED	Early Chemotherapy Based on CA 125 Level Alone Compared With Delayed Chemotherapy in Treating Patients With Recurrent Ovarian Epithelial , Fallopian Tube, or Primary Peritoneal Cancer
NCT00003120	PHASE3	COMPLETED	S9701 Paclitaxel in Treating Patients With Advanced Ovarian, Fallopian Tube, or Primary Peritoneal Cancer in Remission
NCT00003636	PHASE3	COMPLETED	Chemotherapy Plus Surgery in Treating Patients With Stage III or Stage IV Ovarian, Peritoneal, or Fallopian Tube Cancer
NCT00004934	PHASE3	COMPLETED	Paclitaxel and Carboplatin With or Without Epirubicin in Treating Patients With Stage IIB, Stage III, or Stage IV Invasive Ovarian Epithelial, Fallopian Tube, or Peritoneal Cancer
NCT00006454	PHASE3	COMPLETED	Paclitaxel Plus Carboplatin With or Without Topotecan in Treating Patients With Stage IIB, Stage III, or Stage IV Ovarian Epithelial Cancer
NCT00028743	PHASE3	COMPLETED	Combination Chemotherapy Regimens in Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer
NCT00033605	PHASE3	COMPLETED	Octreotide in Preventing Diarrhea in Patients Who Are Undergoing Radiation Therapy to the Pelvis
NCT00041080	PHASE3	COMPLETED	Tamoxifen Compared With Thalidomide in Treating Women With Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
NCT00045461	PHASE2/PHASE3	UNKNOWN	Combination Chemotherapy With or Without Whole-Body Hyperthermia in Treating Patients With Recurrent Ovarian Epithelial, Fallopian Tube, or Peritoneal Cancer
NCT00052468	PHASE3	COMPLETED	Carboplatin/Paclitaxel +/-Gemcitabine in Treating Patients With Ovarian Epithelial or Fallopian Tube Cancer
NCT00075712	PHASE2/PHASE3	COMPLETED	Timing of Surgery and Chemotherapy in Treating Patients With Newly Diagnosed Advanced Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Cancer
NCT00098878	PHASE3	COMPLETED	Carboplatin in Treating Patients With Stage IC-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
NCT00108745	PHASE3	UNKNOWN	Paclitaxel, Polyglutamate Paclitaxel, or Observation in Treating Patients With Stage III or Stage IV Ovarian Epithelial, Peritoneal Cancer, or Fallopian Tube Cancer
NCT00189553	PHASE3	COMPLETED	Caelyx Plus Carboplatin Versus Paclitaxel Plus Carboplatin in Patients With Epithelial Ovarian Cancer in Late Relapse
NCT00226915	PHASE3	COMPLETED	Trial of Tri-weekly TJ Versus Weekly TJ for Stage II-IV Mullerian Carcinoma
NCT00245050	PHASE3	COMPLETED	Pyridoxine in Preventing Hand-Foot Syndrome in Patients Who Are Receiving Liposomal Doxorubicin for Cancer

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
PACLITAXEL	4	123
TOPOTECAN	4	35
MIRVETUXIMAB SORAVTANSINE	4	12
NIRAPARIB	4	11
OLAPARIB	4	10
RUCAPARIB	4	10
CARBOPLATIN	4	5
TAMOXIFEN	4	5
DOXORUBICIN	4	4
ERLOTINIB HYDROCHLORIDE	4	4
PYRIDOXINE	4	3
ATEZOLIZUMAB	4	2
GEMCITABINE HYDROCHLORIDE	4	2
IFOSFAMIDE	4	2
IXABEPILONE	4	2
PEGFILGRASTIM	4	2
PEGINTERFERON ALFA-2B	4	2
SORAFENIB TOSYLATE	4	2
ALVIMOPAN	4	1
AMIFOSTINE	4	1
APREPITANT	4	1
BEVACIZUMAB	4	1
BICALUTAMIDE	4	1
CISPLATIN	4	1
EPIRUBICIN HYDROCHLORIDE	4	1
ERLOTINIB	4	1
ETOPOSIDE PHOSPHATE	4	1
GANCICLOVIR	4	1
GEFITINIB	4	1
GOSERELIN	4	1

Precision-medicine subtype map (CIViC)

Drug × molecular subtype: 1 predictive associations from 1 curated evidence items.

Molecular subtype	Therapy	Effect	Level	CIViC
BRCA1 Mutation OR BRCA2 Mutation	Niraparib	Sensitivity/Response	CIViC A	EID11305